These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 24262879)

  • 1. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome.
    Nelson GS; Pink A; Lee S; Han G; Morris D; Ogilvie T; Duggan MA; Köbel M
    Gynecol Oncol; 2013 Nov; 131(2):309-14. PubMed ID: 23938375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
    Catasus L; Gallardo A; Cuatrecasas M; Prat J
    Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
    McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
    J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.
    Catasus L; Gallardo A; Cuatrecasas M; Prat J
    Mod Pathol; 2008 Feb; 21(2):131-9. PubMed ID: 18084252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
    Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T
    Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
    Lax SF; Kurman RJ
    Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma.
    Vaziri Fard E; Imboden S; Rau T; Epstein E; Petta TB; Walia S; Carlson JW
    Int J Gynecol Pathol; 2024 Sep; 43(5):515-526. PubMed ID: 39164940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
    Quddus MR; Sung CJ; Zhang C; Lawrence WD
    Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.